Consensus Chemed Corporation

Equities

CHE

US16359R1032

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
641.9 USD -0.36% Intraday chart for Chemed Corporation -0.31% +9.78%

Evolution of the average Target Price on Chemed Corporation

Price target over the last 5 years

History of analyst recommendation changes

dcb7a.pAem3RfVj6do7-LvCgRb6mDIRYOwfusCMi4lBPdVEs4.3W7UlC-U4cgkt5q3SH4DtQuBDevcFdlPdxtgXMAMd4nWXs-wQ-31ygCllQ~014933baacbfaf67b7a6822448b550a8
Chemed Insider Sold Shares Worth $1,704,321, According to a Recent SEC Filing MT
Chemed Insider Sold Shares Worth $7,196,910, According to a Recent SEC Filing MT
RBC Boosts Price Target on Chemed to $712 From $604, Expects 'Strong' VITAS Momentum to Continue in 2024; Outperform Kept MT
Oppenheimer Raises Chemed Price Target to $650 From $625, Maintains Outperform Rating MT
Oppenheimer Adjusts Chemed Price Target to $625 From $590, Maintains Outperform Rating MT
RBC Raises Price Target on Chemed to $604 From $576, Keeps Outperform Rating MT
RBC Cuts Price Target on Chemed to $576 From $610, Maintains Outperform Rating MT
Oppenheimer Adjusts Chemed Price Target to $590 From $610, Maintains Outperform Rating MT
RBC Boosts Price Target on Chemed to $610 From $587 After 'Solid Results,' Maintains Outperform Rating MT
Oppenheimer Raises Chemed's Price Target to $610 From $580, Maintains Outperform Rating MT
RBC Raises Price Target on Chemed to $587 From $545, Maintains Outperform Rating MT
RBC Raises Price Target on Chemed to $545 From $541, Maintains Outperform Rating MT
RBC Cuts Price Target on Chemed to $541 From $592, Citing Recent Industry Multiple Compression, Maintains Outperform Rating MT
RBC Boosts Price Target on Chemed to $592 From $579, Maintains Outperform Rating MT
RBC Cuts Price Target on Chemed to $579 From $609, Maintains Outperform Rating MT
CHEMED : RBC Boosts Price Target on Chemed to $609 From $604, Citing Strong Roto-Rooter Growth, Maintains Outperform Rating MT
CHEMED : RBC Boosts Price Target on Chemed to $604 From $600, Sees Guidance Raise Likely, Maintains Outperform Rating MT
CHEMED : Oppenheimer Adjusts Chemed PT to $580 From $600, Maintains Outperform Rating MT
CHEMED : Oppenheimer Adjusts Chemed's Price Target to $600 From $535, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
641.9 USD
Average target price
690 USD
Spread / Average Target
+7.49%
High Price Target
712 USD
Spread / Highest target
+10.92%
Low Price Target
650 USD
Spread / Lowest Target
+1.26%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Chemed Corporation

RBC Capital Markets
Oppenheimer
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings